We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Announces Data Presentations at the SITC 2018 Annual Meeting
WALTHAM, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from a total of five abstracts will be presented at the Society for Immunotherapy of Cancer ( SITC ) Annual Meeting from November 7-11, 2018 in
View HTML
Toggle Summary TESARO Announces Participation at Two Investor Conferences
WALTHAM, Mass. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:         The Cantor Global Healthcare Conference at the InterContinental
View HTML
Toggle Summary TESARO Announces Expansion to Second Stage of JASPER Trial of ZEJULA® in Combination With TSR-042 in Non-Small Cell Lung Cancer
All evaluable patients experienced tumor shrinkage Protocol defined response criteria achieved and trial expansion ongoing WALTHAM, Mass. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced it has initiated the second
View HTML
Toggle Summary TESARO Announces Participation at Three Investor Conferences
WALTHAM, Mass. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are: Citi’s 13 th Annual Biotech Day at the Four Seasons Hotel in Boston on
View HTML
Toggle Summary TESARO Announces Second-Quarter 2018 Operating Results
ZEJULA ® Q2 net sales totaled $54 million compared to $26 million for Q2 2017 QUADRA sNDA submission planned for Q4 2018 PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of biomarker status enrollment completed Divestiture completed for VARUBI in U.S.
View HTML
Toggle Summary TESARO to Announce Second-Quarter 2018 Financial Results on August 2, 2018
WALTHAM, Mass. , July 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce second-quarter 2018 financial results on Thursday, August 2, 2018 , after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at 4:15
View HTML
Toggle Summary TESARO Partners With the Pan-Mass Challenge for 2018 Ride Benefiting Dana-Farber Cancer Institute
WALTHAM, Mass. , July 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce a new partnership supporting the Pan-Mass Challenge (PMC). The PMC is the nation’s most successful athletic fundraising event, raising money for cancer
View HTML
Toggle Summary TESARO Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing
WALTHAM, Mass. , June 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has drawn the $200 million second tranche under its term loan agreement with BIOPHARMA CREDIT PLC and BIOPHARMA CREDIT INVESTMENTS IV SUB LP,
View HTML
Toggle Summary TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada
TESARO to Receive $40 Million , plus Potential for Additional Milestone Payments and Royalties TESARO Retains ex-North America Rights and Continues to Market VARUBY ® in Europe WALTHAM, Mass. , June 28, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical
View HTML
Toggle Summary TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
WALTHAM, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group , to evaluate the combination of the PD-L1 antibody
View HTML